Claims
- 1. A compound of formula I
- 2. The compound according to claim 1 wherein W is SO2.
- 3. The compound according to claim 1 wherein Z is O.
- 4. The compound according to claim 1 wherein n is 2.
- 5. The compound according to claim 1 wherein R6 is an aryl or heteroaryl group each optionally substituted.
- 6. The compound according to claim 1 wherein X is CR7 and R5 and R7 are H.
- 7. The compound according to claim 2 wherein R1 and R2 are H; Z is O; and n is 2.
- 8. The compound according to claim 6 wherein W is SO2; Z is O; and R3 and R4 are taken together with the atom to which they are attached to form a 5- or 6-membered ring optionally containing one oxygen atom.
- 9. The compound according to claim 6 selected from the group consisting of:
2-{[1-(phenylsulfonyl)-1H-indol-4-yl]oxy}ethylamine; 4-(2-morpholin-4-ylethoxy)-1-(phenylsulfonyl)-1H-indole; 1-(phenylsulfonyl)-4-(2-piperidin-1-ylethoxy)-1H-indole; N-(2-{[1-(phenylsulfonyl)-1H-indol-4-yl]oxy}ethyl)tetrahydro-2H-pyran-4-amine; N,N-bis(3-methoxybenzyl)-2-{[1-(phenylsulfonyl)-1H-indol-4-yl]oxy}ethanamine; N-(3-methoxybenzyl)-2-{[1-(phenylsulfonyl)-1H-indol-4-yl]oxy}ethanamine; N,N-dimethyl-2-{[1-(phenylsulfonyl)-1H-indol-4-yl]oxy}ethanamine; 1-(phenylsulfonyl)-4-[2-(1-piperidinyl)ethoxy]-1H-indazole; 2-{[1-(phenylsulfonyl)-1H-indazol-4-yl]oxy}ethylamine; N-(2-{[1-(phenylsulfonyl)-1H-indazol-4-yl]oxy}ethyl)tetrahydro-2H-pyran-4-amine; N-(2-{[1-(phenylsulfonyl)-1H-indazol-4-yl]oxy}ethyl)tetrahydro-2H-thiopyran-4-amine; 1-[(4-nitrophenyl)sulfonyl]-4-[2-(1-piperidinyl)ethoxy]-1H-indazole; 1-[(4-fluorophenyl)sulfonyl]-4-[2-(1-piperidinyl)ethoxy]-1H-indazole; 4-({4-[2-(1-piperidinyl)ethoxy]-1H-indazol-1-yl}sulfonyl)aniline; and a pharmaceutically acceptable salt thereof.
- 10. A method for the treatment of a disorder of the central nervous system related to or affected by the 5-HT6 receptor in a patient in need thereof which comprises providing to said patient a therapeutically effective amount of a compound of formula I.
- 11. The method according to claim 10 wherein said disorder is a motor disorder, anxiety disorder or cognitive disorder.
- 12. The method according to claim 10 wherein said disorder is schizophrenia or depression.
- 13. The method according to claim 11 wherein said cognitive disorder is attention deficit disorder.
- 14. The method according to claim 11 wherein said cognitive disorder is Alzheimer's disease or Parkinson's disease.
- 15. A pharmaceutical composition which comprises a pharmaceutically acceptable carrier and an effective amount of a compound of formula I.
- 16. The composition according to claim 15 wherein W is SO2; Z is O; and n is 2.
- 17. The composition according to claim 16 wherein R6 is an aryl or heteroaryl group each optionally substituted.
- 18. The composition according to claim 17 wherein X is CR7 and R1, R2, R5, and R7 are H.
- 19. The composition according to claim 18 having a formula I compound selected from the group consisting of:
2-{[1-(phenylsulfonyl)-1H-indol-4-yl]oxy}ethylamine; 4-(2-morpholin-4-ylethoxy)-1-(phenylsulfonyl)-1H-indole; 1-(phenylsulfonyl)-4-(2-piperidin-1-ylethoxy)-1H-indole; N-(2-{[1-(phenylsulfonyl)-1H-indol-4-yl]oxy}ethyl)tetrahydro-2H-pyran-4-amine; N,N-bis(3-methoxybenzyl)-2-{[1-(phenylsulfonyl)-1H-indol-4-yl]oxy}ethanamine; N-(3-methoxybenzyl)-2-{[1-(phenylsulfonyl)-1H-indol-4-yl]oxy}ethanamine; N,N-dimethyl-2-{[1-(phenylsulfonyl)-1H-indol-4-yl]oxy}ethanamine; 1-(phenylsulfonyl)-4-[2-(1-piperidinyl)ethoxy]-1H-indazole; 2-{[1-(phenylsulfonyl)-1H-indazole-4-yl]oxy}ethylamine; N-(2-{[1-(phenylsulfonyl)-1H-indazole-4-yl]oxy}ethyl)tetrahydro-2H-pyran-4-amine; N-(2-{[1-(phenylsulfonyl)-1H-indazol-4-yl]oxy}ethyl)tetrahydro-2H-thiopyran-4-amine; 1-[(4-nitrophenyl)sulfonyl]-4-[2-(1-piperidinyl)ethoxy]-1H-indazole; 1-[(4-fluorophenyl)sulfonyl]-4-[2-(1-piperidinyl)ethoxy]-1H-indazole; 4-({4-[2-(1-piperidinyl)ethoxy]-1H-indazole-1-yl}sulfonyl)aniline; or a pharmaceutically acceptable salt thereof.
- 20. A method for the preparation of a compound of formula Ia
BACKGROUND OF THE INVENTION
[0001] This is a divisional of copending application Ser. No. 10/055,365 filed on Jan. 22, 2002 the entire disclosure of which is hereby incorporated by reference.
[0002] This application claims priority from copending application Serial No. 60/263,425, filed on Jan. 23, 2001, the entire disclosure of which is hereby incorporated by reference.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60263425 |
Jan 2001 |
US |
Divisions (1)
|
Number |
Date |
Country |
Parent |
10055365 |
Jan 2002 |
US |
Child |
10314726 |
Dec 2002 |
US |